New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:06 EDTARNAArena Pharmaceuticals initiates Phase 1b clinical trial of APD334
Arena Pharmaceuticals announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:18 EDTARNAArena Pharmaceuticals' APD811 granted orphan drug status
Subscribe for More Information
August 31, 2014
14:04 EDTARNAWorldwide Business Research to hold a conference
Subscribe for More Information
August 29, 2014
11:04 EDTARNAArena pulmonary arterial hypertension treatment granted orphan designation
The FDA granted orphan designation to Arena Pharmaceuticals' treatment of pulmonary arterial hypertension, according to a post to the agency's site. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use